# Effects of an increased financial incentive on follow-up in an online, automated smoking cessation trial: A randomised controlled Study Within a Trial (SWAT)

Juliet High MChem<sup>1</sup>, Kelly Grant<sup>1</sup>, Aimie Hope PhD<sup>2,3</sup>, Lee Shepstone PhD<sup>1</sup>, Claire West PhD, Antony

Colles<sup>1</sup>, Felix Naughton PhD<sup>2,3</sup>

CCK

Corresponding author: Felix Naughton, f.naughton@uea.ac.uk, School of Health Sciences, University of East Anglia, Norwich, Norfolk, NR4 7TJ. ORCID: 0000-0001-9790-2796

<sup>1</sup> Norwich Clinical Trials Unit, University of East Anglia, UK

- <sup>2</sup> Behavioural and Implementation Science Group, School of Health Sciences, University of East Anglia
- <sup>3</sup> Addiction Research Group, Norwich Medical School, University of East Anglia, UK

#### ABSTRACT

**Introduction:** Poor retention in clinical trials can impact on statistical power, reliability, validity and generalisability of findings and is a particular challenge in smoking cessation studies. In online trials with automated follow up mechanisms, poor response also increases resource-need for manual follow up. This study compared two financial incentives on response rates at 6 months follow up, in an online, automated smoking cessation feasibility trial of a cessation smartphone app (Quit Sense).

**Methods**: A study within a trial (SWAT), embedded within a host randomised controlled trial. Host trial participants were randomised 1:1 to receive either a £10 or £20 voucher incentive, for completing the 6-month questionnaire. Stratification for randomisation to the SWAT was by minimisation to ensure an even split of host trial arm participants, and by 6-week response rate. Outcome measures were: questionnaire completion rate, time to completion, number of completers requiring manual follow up and completeness of responses.

**Results:** 204 participants were randomised to the SWAT. The £20 and £10 incentives did not differ in completion rate at 6 months (79% versus 74%; p=0.362) but did reduce the proportion of participants requiring manual follow up (46% versus 62%; p=0.018) and the median completion time (7 days versus 15 days; p=0.008). Measure response completeness rates were higher among £20 incentive participants, though differences were small for the host trial's primary smoking outcome.

**Conclusions:** Benefits to using relatively modest increases in incentive for online smoking cessation trials include more rapid completion of follow up questionnaires and reduced manual follow up.

Keywords: smoking cessation; randomised controlled trial; SWAT; incentive; retention

Trial registration: Host trial ISRCTN12326962, SWAT repository store ID 164

## IMPLICATIONS

A modest increase in incentive (from £10 to £20) to promote the completion of follow up questionnaires in online smoking cessation trials may not increase overall response rates but could lead to more rapid data collection, a reduced need for manual follow-up and reduced missing data among those who initiate completing a questionnaire. Such an improvement may help to reduce bias, increase validity and generalisability, and improve statistical power in smoking cessation trials.

### INTRODUCTION

Poor retention of participants in clinical trials and the resulting missing outcome data is a consistently documented challenge.<sup>1,2</sup> The impacts include potential selection bias in results, reduced statistical power and reduced reliability, validity, and generalizability of the trial findings. Schultz et al<sup>3</sup> propose that a loss of greater than 20% potentially poses a threat to the validity of the study.<sup>3</sup> However, all gains in collection of outcome data can have a meaningful impact<sup>4</sup> so it is important that options are explored to improve retention in trials.

Retention of participants can be more challenging when trials are conducted remotely or wholly online<sup>5</sup> and when there is minimal contact with participants due to non-interpersonal treatment delivery. For smoking cessation treatment, there are perceptions from participants that if they have not stopped smoking their data is no longer useful, hence the common application of a "missing = smoking" rule among those lost to follow-up.<sup>6</sup> This further compounds the challenge of ensuring representative outcome data and retention rates in smoking cessation trials. Some online smoking cessation trials investigating remote treatments that have used incentives have achieved relatively high positive 6month response rates, such as 77% returning a saliva sample who received a £20 incentive,<sup>7</sup> and 88% retained who received a \$25 incentive plus a \$10 bonus if done within 24 hours of notification.<sup>8</sup> However, a Cochrane review (2017) of web-based smoking cessation trials identified that the majority of included studies achieved between 50-80% follow up rates.<sup>9</sup> The extent to which incentives promote response in smoking cessation trials largely unknown, particularly for remote and online trials.

Literature reviews investigating studies outside of smoking cessation find incentives improve retention and response rates, particularly for remote trials.<sup>10-12</sup> For example, Bailey et al<sup>13</sup> found postal response rates increased by 6-10% through increasing the offered incentive from £10 to £20. We embedded a randomised Study Within A Trial (SWAT)<sup>14</sup> in an online and automated feasibility randomised controlled trial of a stop smoking smartphone app called Quit Sense, to understand the impact of offering a £20 incentive compared to a £10 incentive on: 1) participant response on their smoking status at 6 months follow-up by all methods, 2) number of participants requiring manual follow up, 3) completeness of response from all follow-up questions asked. The trial results will inform which incentive rate to use in a future definitive trial of the Quit Sense app.

#### **METHODS**

#### **Design and participants**

A two-arm parallel randomised controlled study within a host trial<sup>15</sup> was undertaken. The host trial recruited 209 patients to a randomised controlled trial comparing a Just-In-Time Adaptive Intervention (JITAI) smoking cessation smartphone app (Quit Sense), to online standard care for smoking cessation (NHS SmokeFree website) only.<sup>16</sup> In the host trial, randomisation was stratified by smoking rate (<16 vs ≥16 cigarettes per day) and socioeconomic status (low vs high). Recruitment, enrolment, baseline data collection, allocation and intervention access delivery were automated through the study website. Outcomes were collected at 6 weeks and 6 months follow up via the study website via a text message or email prompt or, if an initial response was not received, by telephone.

All participants of the host trial who had not withdrawn by the 6-week follow up, were randomised into the SWAT using minimisation.<sup>17</sup> Minimisation ensured an equal balance between the SWAT (incentive) groups, accounting for the participants' host trial allocation group, and whether they responded at 6

weeks follow up. Allocation to the incentive groups was carried out in R using the minirand package, and then the results imported into REDCap.<sup>18,19</sup>

The researcher was unaware of incentive group allocation when undertaking manual follow-up calls although was not blinded to incentive group as they needed to allocate vouchers when follow up was completed using the REDCap database. Participants were blinded to their incentive allocation up until the incentive was offered at 6 months follow-up and were not informed at any point that the incentive amount offered was different for some participants.

Participants were offered a £5 Amazon gift voucher for completing the 6-week follow-up. Participants were informed in the participant information sheet they would receive a £10 voucher code for completing 6-month follow-up, but as the SWAT was conceived after all participants were recruited, they were not aware of the additional £10 incentive offered to some participants.

Additional consent to the SWAT was not sought as this was deemed unnecessary as all participants would still receive the £10 6-month incentive as indicated and informing the £10 incentive SWAT arm that they received less than the £20 arm could have biased the findings. The SWAT was approved by the Wales NHS Research Ethics Committee 7 (19/WA/0361) as an amendment to the host trial ethics application.

The detailed plan for the SWAT and incentive rates were reviewed and agreed upon by a Patient and Public representative on the host trial management group and the SWAT was registered on the SWAT Repository Store (ID 164).

The sample size of this SWAT was dependent on the sample size used in the host trial, and so a formal power calculation was not undertaken.

Refer to the host trial outcomes paper<sup>16</sup> for a description of host trial measures.

#### Procedure

Six and a half months after enrolment (referred to as the 6-month follow-up, allowing two weeks for setting and preparing for a quit attempt), all participants were sent an automated text message inviting them to complete the final questionnaire. This message differed between groups only by the incentive amount they would receive (£10 or £20) (see supplementary figure 1 for text message wording).

An automated reminder text message and a text message explaining the researchers would contact them by telephone if they did not complete the questionnaire online was sent 4 and 7 days later respectively. Participant stating email as a preferred contact method were sent the questionnaire link and reminders by email instead, although very few did. Two weeks after the questionnaire due date, the Researcher attempted manual follow-up by telephone and, if unsuccessful, a final text message inviting them to respond to the primary smoking outcome question was sent.

Other strategies to try and improve overall response rates in the trial were used for all participants, including text reminders about participation and a "thank you" postcard.

## Analysis

Sample characteristics at baseline (by incentive arm) and completeness of responses are summarised, though no statistical comparisons were planned or undertaken. For the overall response rate analysis, a logistic regression model was run, using Wald confidence intervals for the odds ratio, including stratification variables as covariates in the model and any participant characteristics that appeared imbalanced between the different incentive groups (prognostic variables), with response (binary) as the dependent variable. For the other analyses, further logistic regression models were run using an analogous approach for assessing the effect of incentives on manual follow up rates. Results from regression analyses are presented separately as unadjusted, adjusted for stratification variables and then adjusted for stratification and potential prognostic factors. Finally, a Cox proportional hazards analysis was undertaken with the log-rank test to assess the effects of incentives on completion time. Outcomes are described as proportions or summary statistics with 95% Cls.

#### RESULTS

204 participants were included in the Quit Sense SWAT, 101 randomised to the £20 incentive arm and 103 to the £10 arm.

The SWAT sample had a mean age of 41 years (range 18-61), 55% female, 29% were in the lowest socioeconomic status category, 9% had other-than-white ethnicity and mean baseline smoking rate was 15 cigarettes per day (Table 1).

In the host trial, more participants provided data at 6 months than at 6 weeks. At 6 weeks, 149 (71%; 95% CI 65%, 77%) were followed up and at 6 months, when the incentive rate was manipulated, this was 160 (77%; 95% CI 71%, 82%). There were 6 host trial withdrawals, with 5 withdrawing prior to SWAT randomisation (and so excluded) and one between 6 weeks and 6 months.

At 6-months follow up, there was no statistically significant difference in overall response rate between participants offered a £20 voucher incentive compared with a £10 incentive (79% vs. 74%, unadjusted OR=1.35; 95% CI 0.71, 2.60; p=0.36; fully adjusted OR=1.29; 95% CI 0.66, 2.54; p=0.46) (Table 2), though

the results favoured the £20 incentive group. However, the need for manual follow-up, due to questionnaires not being completed from digital prompts, differed between incentive groups; 46% of those in the £20 incentive group required manual follow up compared with 62% of the £10 incentive group (unadjusted OR=0.51, 95% CI 0.29, 0.89, p=0.018; fully adjusted OR=0.53; 95% CI 0.29, 0.95; p=0.032).

The log-rank test, which compares expected and observed questionnaire completions over time by incentive group, shows moderate evidence that there was a difference in survival probability between incentive groups, with the £20 incentive group showing on average a lower completion time (median: 7.0 days, IQR 0.08, 18.13) than the £10 incentive group (median: 14.9 days, IQR 0.15, 24.55), which was statistically significant (unadjusted p=0.008) (Table 2). This is confirmed by a Cox proportional hazards analysis showing that at any point in time, the £20 incentive group were 55% more likely to respond to the 6-month questionnaire, compared to those participants in the £10 incentive group (unadjusted HR=1.55, 95% CI 1.12, 2.15, p=0.008). The failure plot (Supplementary Figure 2) suggests that failure probability increased over time, with a higher probability of completing the 6-month questionnaire when close to 0 days. Adjusting for stratification and prognostic variables for the above analyses did not alter the findings meaningfully.

Completeness of data for questionnaire items other than the overall response rate were also higher in the £20 incentive group compared to the £10 group (Supplementary Table 1). For example, 78% versus 68% of participants reported urge items data and 78% versus 66% completed EQ-5D-5L questions in the £20 and £10 incentive groups respectively, though between-group differences for response to the primary outcome were smaller (79% versus 74%).

## DISCUSSION

Increasing the incentive for completing follow up from £10 to £20 did not increase overall response rates at 6 months. However, it did reduce the proportion of participants requiring manual follow-up and the median completion time and may increase the completeness of some data. It is possible that incentives influence response to remote or non-interpersonal follow up prompts more than response to interpersonal efforts. This is suggested by the beneficial effect of increased incentives on manual follow up rates, where, if manual follow up was not undertaken, a difference in overall response rates would potentially have been observed. Speeding up completion times could contribute to enhanced validity through a reduction in variability in response delay and would likely lead to other potential benefits such as a more rapid collection of saliva samples, when verifying those reporting abstinence.

If higher completeness of data is achieved, this would enhance statistical power and validity through reduced missing data. While higher incentives increase the overall incentive costs, these could be, at least in part, offset by reduced researcher costs with fewer participants to manually follow up. Furthermore, it is possible that an incentive higher than £20 may increase the response rate to a satisfactory level that would avoid the need for any manual follow up, though further research would be needed to determine this, and the optimum level and type of incentive, noting that there is likely to be a ceiling effect.<sup>20</sup> The overall response rate in the £20 incentive arm was very similar to another UK digital cessation intervention trial with a comparable incentive<sup>7</sup> and the non-significant increase in response rates observed was in line with increased postal response rates found from increasing an incentive from £10 to £20 for an online intervention.<sup>13</sup>

This trial was automated, though where necessary participants were followed up by phone call. It is unclear whether the same incentive amounts would work as well in a different healthcare setting or population, particularly where motivations may be different. Response rates were in-line with or perhaps slightly higher than literature reported rates for similar trials,<sup>9</sup> indicating that appropriate incentives may help to achieve an acceptable response and retention rate.

Strengths of this SWAT include robust randomisation and intervention delivery fidelity. Arms were well balanced for most baseline characteristics and key imbalances accounted for in the adjusted analyses. Participants were also effectively blinded from incentive allocation, so their response was likely to reflect the effect of the incentive within the context of the trial. However, it is possible some participants may have recalled the original incentive from the participant information sheet before the SWAT was embedded in the trial, and those offered £20 may have felt the increased incentive was a bonus or upgrade, which could have influenced the effects observed.

### Conclusion

While overall response rates were not increased, the potential benefit of a more rapid completion of follow up questionnaires, a reduced need for manual follow-up and potentially increased measure completion rates from a relatively modest increase in incentive costs may be worthwhile, particularly in the context of the high costs of running smoking cessation clinical trials and value of follow up data.

# FUNDING

This study is funded by the NIHR Public Health Research Programme (17/92/31). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

# **DECLARATION OF INTERESTS**

FN is an unpaid member of the scientific committee for the Smoke Free app, a smoking cessation app unrelated to this project. The remaining authors have no interests to declare.

# DATA AVAILABILITY STATEMENT

The data underlying this article will be shared on reasonable request to the corresponding author.

# ACKNOWLEDGEMENTS

The authors are very grateful to the following for their contribution, time and efforts in ensuring the success of this project: the participants, the patient and public involvement and engagement panel, the Norwich Clinical Trials Unit and NHS Norfolk and Waveney ICB.

## REFERENCES

1. Akl EA, Briel M, You JJ, et al. Potential impact on estimated treatment effects of information lost to follow-up in randomised controlled trials (LOST-IT): systematic review. *BMJ*. May 18 2012;344:e2809. doi:10.1136/bmj.e2809

2. Severi E, Free C, Knight R, Robertson S, Edwards P, Hoile E. Two controlled trials to increase participant retention in a randomized controlled trial of mobile phone-based smoking cessation support in the United Kingdom. *Clin Trials*. Oct 2011;8(5):654-60. doi:10.1177/1740774511416524

3. Schulz KF, Grimes DA. Sample size slippages in randomised trials: exclusions and the lost and wayward. *Lancet*. Mar 2 2002;359(9308):781-5. doi:10.1016/S0140-6736(02)07882-0

4. Trial Forge. <u>https://www.trialforge.org/</u>. 2023.

5. Watson NL, Mull KE, Heffner JL, McClure JB, Bricker JB. Participant Recruitment and Retention in Remote eHealth Intervention Trials: Methods and Lessons Learned From a Large Randomized Controlled Trial of Two Web-Based Smoking Interventions. *J Med Internet Res.* Aug 24 2018;20(8):e10351. doi:10.2196/10351

6. West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. *Addiction*. 2005;100(3):299-303. doi:10.1111/j.1360-0443.2004.00995.x

7. Brown J, Michie S, Geraghty AW, et al. Internet-based intervention for smoking cessation (StopAdvisor) in people with low and high socioeconomic status: a randomised controlled trial. *Lancet Respir Med*. Dec 2014;2(12):997-1006. doi:10.1016/S2213-2600(14)70195-X

8. Bricker JB, Watson NL, Mull KE, Sullivan BM, Heffner JL. Efficacy of Smartphone Applications for Smoking Cessation: A Randomized Clinical Trial. *JAMA Intern Med*. Nov 1 2020;180(11):1472-1480. doi:10.1001/jamainternmed.2020.4055

9. Taylor GMJ, Dalili MN, Semwal M, Civljak M, Sheikh A, Car J. Internet-based interventions for smoking cessation. *Cochrane Database Syst Rev.* Sep 4 2017;9(9):CD007078. doi:10.1002/14651858.CD007078.pub5

10. Hewitt CE, Kumaravel B, Dumville JC, Torgerson DJ, Trial attrition study g. Assessing the impact of attrition in randomized controlled trials. *J Clin Epidemiol*. Nov 2010;63(11):1264-70. doi:10.1016/j.jclinepi.2010.01.010

11. Gillies K, Kearney A, Keenan C, et al. Strategies to improve retention in randomised trials. *Cochrane Database Syst Rev.* Mar 6 2021;3(3):MR000032. doi:10.1002/14651858.MR000032.pub3

12. Arundel C, Coleman E, Fairhurst C, Peckham E, Bailey D, Gilbody S. The effectiveness of a contingent financial incentive to improve trial follow up; a randomised study within a trial (SWAT). *F1000Res*. 2019;8:1937. doi:10.12688/f1000research.21059.2

13. Bailey JV, Pavlou M, Copas A, et al. The Sexunzipped trial: optimizing the design of online randomized controlled trials. *J Med Internet Res*. Dec 11 2013;15(12):e278. doi:10.2196/jmir.2668 14. SWAT Store.

https://www.qub.ac.uk/sites/TheNorthernIrelandNetworkforTrialsMethodologyResearch/SWATSWARIn formation/Repositories/SWATStore/. 2023.

15. Naughton F, Brown C, High J, et al. Randomised controlled trial of a just-in-time adaptive intervention (JITAI) smoking cessation smartphone app: the Quit Sense feasibility trial protocol. *BMJ Open*. Apr 26 2021;11(4):e048204. doi:10.1136/bmjopen-2020-048204

16. Naughton F, Hope A, Siegele-Brown C, et al. An Automated, Online Feasibility Randomized Controlled Trial of a Just-In-Time Adaptive Intervention for Smoking Cessation (Quit Sense). *Nicotine Tob Res.* Jun 9 2023;25(7):1319-1329. doi:10.1093/ntr/ntad032

17. Altman DG, Bland JM. Treatment allocation by minimisation. *BMJ*. Apr 9 2005;330(7495):843. doi:10.1136/bmj.330.7495.843

18. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software platform partners. *J Biomed Inform*. Jul 2019;95doi:ARTN 103208

# 10.1016/j.jbi.2019.103208

, cce

19. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform*. Apr 2009;42(2):377-381. doi:10.1016/j.jbi.2008.08.010

20. Parkinson B, Meacock R, Sutton M, et al. Designing and using incentives to support recruitment and retention in clinical trials: a scoping review and a checklist for design. *Trials*. Nov 9 2019;20(1):624. doi:10.1186/s13063-019-3710-z

Table 1 Participant characteristics at baseline

	£20 incentive	£10 incentive	Overall
	(n=101)	(n=103)	(n=204)
Host trial intervention group: n (%)	49 (48.5%)	51 (49.5%)	100 (49.0%)
Age at consent: mean (SD)	42.0 (9.6)	40.3 (10.6)	41.1 (10.2)
Gender: n (%)			
- Male	51 (50.5%)	40 (38.8%)	91 (44.6%)
- Female	50 (49.5%)	63 (61.1%)	113 (55.4%)
Number of cigarettes smoked per day: n (%)			
- Less than 16	63 (62.4%)	62 (60.2%)	125 (61.3%)
- 16 or more	38 (37.6%)	41 (39.8%)	79 (38.7%)
Socioeconomic status <sup>a</sup> : n (%)			
- Low	33 (32.7%)	26 (25.2%)	59 (28.9%)
- High	68 (67.3%)	77 (74.8%)	145 (71.1%)
Missing	27	27	54
Ethnicity: n (%)			
- White	91 (90.1%)	95 (92.2%)	186 (91.2%)
- Indian	1 (1.0%)	0	1 (0.5%)
- Pakistani	0	2 (1.9%)	2 (1.0%)
- Bangladeshi	2 (2.0%)	1 (1.0%)	3 (1.5%)
- Black African	0	2 (1.9%)	2 (1.0%)
- Black (Other)	1 (1.0%)	0	1 (0.5%)
- Asian	3 (3.0%)	0	3 (1.5%)
- Mixed Race	2 (2.0%)	1 (1.0%)	3 (1.5%)
- Not given	1 (1.0%)	2 (1.9%)	3 (1.5%)
Number of cigarettes smoked a day: mean	15.6 (7.1)	15.3 (6.8)	15.4 (6.9)
(SD)			
Employment Status: n (%)			
<ul> <li>In work during last 12 months</li> </ul>	74 (73.3%)	75 (72.8%)	149 (73.0%)
<ul> <li>Out of work for more than 12 months</li> </ul>	26 (25.7%)	19 (18.5%)	45 (22.1%)
- Retired	0	1 (1.0%)	1 (0.5%)
Full time student	1 (1.0%)	8 (7.8%)	9 (4.4%)
Occupation: n (%)			
- Modern Professional	20 (27.0%)	17 (22.4%)	37 (24.7%)
- Clerical	10 (13.5%)	8 (10.5%)	18 (12.0%)
<ul> <li>Senior Manager/Administration</li> </ul>	11 (14.9%)	11 (14.5%)	22 (14.7%)
- Technical	10 (13.5%)	5 (6.6%)	15 (10.0%)
- Semi Routine Manual/Service	6 (8.1%)	11 (14.5%)	17 (11.3%)
- Routine Manual/Service	5 (6.8%)	4 (5.3%)	9 (6.0%)
<ul> <li>Middle/Junior Manager</li> </ul>	8 (10.8%)	8 (10.5%)	16 (10.7%)
- Traditional Professional	4 (5.4%)	12 (15.8%)	16 (10.7%)
Missing	27	27	54

Highest Qualification: n (%)			
- No formal	9 (8.9%)	4 (3.9%)	13 (6.4%)
- GCSE or similar	24 (23.8%)	18 (17.5%)	42 (20.6%)
<ul> <li>A/AS Level or similar</li> </ul>	28 (27.7%)	23 (22.3%)	51 (25.0%)
- Degree or similar	36 (35.6%)	50 (48.5%)	86 (42.2%)
- Other	4 (4.0%)	8 (7.8%)	12 (5.9%)

<sup>a</sup> Low socioeconomic status was classified as individuals with a semi-routine or routine and manual occupation (grade five in the National Statistics Socio-Economic Classification), or who have never worked or are long-term unemployed. High socioeconomic status included all those not classed as low status.

Table 2: Effects of incentive value on response rate of the smoking status question at 6 months (self-reported prolonged abstinence), rate of manual follow up at 6 months and completion time (days) to completing the smoking status question at 6 months (in days)

Model <sup>a</sup>	£20 incentive	£10 incentive	Odds	95% Wald	p-value <sup>d</sup>			
N = 204	N = 101	N = 103	ratio	Interval <sup>c</sup>				
Overall response rate (n [%])								
Incentive group only	80 (79.2%)	76 (73.8%)	1.35	(0.71, 2.60)	0.362			
(unadjusted)								
Adjusted model, including								
incentive group and	80 (79.2%)	76 (73.8%)	1.38	(0.71, 2.69)	0.337			
stratification variables								
Adjusted model, including								
incentive group, stratification	80 (79.2%)	76 (73.8%)	1.29	(0.66, 2.54)	0.462			
and prognostic variables								
Rate of manual follow up (n [%])								
Incentive group only								
(unadjusted)	46 (45.5%)	64 (62.1%)	0.51	(0.29, 0.89)	0.018			
Adjusted model, including								
incentive group and	46 (45.5%)	64 (62.1%)	0.53	(0.30, 0.94)	0.030			
stratification variables								
Adjusted model, including								
incentive group, stratification	46 (45.5%)	64 (62.1%)	0.53	(0.29, 0.95)	0.032			
and prognostic variables								
Number of days taken to respond (median [IQR])								
Incentive group only	7.00	14.85		(1.12, 2.15)				
(unadjusted)	(0.08, 18.13)	(0.15, 24.55)	1.55 <sup>e</sup>		0.008			
Adjusted model, including								
incentive group and	7.00	14.85	1.53 <sup>e</sup>	(1.10, 2.12)	0.012			
stratification variables	(0.08, 18.13)	(0.15, 24.55)						
Adjusted model, including								
incentive group, stratification	7.00	14.85	1.53 <sup>e</sup>	(1.10, 2.13)	0.012			
and prognostic variables	(0.08, 18.13)	(0.15, 24.55)						

<sup>a</sup>Logistic regression model used, modelling the odds of response to smoking status at 6 months (<u>self-reported</u> smoking status: where non-smoking is smoking no more than 5 cigarettes within the 6 month study period) and modelling the odds of manual follow-up at 6 months. Both analyses adjusted for differences in number of cigarettes smoked per day at baseline, socioeconomic status at baseline (stratification variables), heaviness index at baseline, gender (prognostic variables) and incentive group.

<sup>b</sup>Odds ratio (OR; the odds of response/manual follow up for participants in the £20 incentive group is (OR) times that of the odds of response for participants in the £10 incentive group).

°95% Wald confidence Interval for odds ratio.

<sup>d</sup>The p-value is based upon a null hypothesis of zero difference.

<sup>e</sup>Hazard ratio (HR; at any particular point in time, the £20 incentive group are (HR) times more likely to respond to the 6-month questionnaire, compared to those participants in the £10 incentive group. If HR<1 (or HR>1), the £20 incentive group experience a 'risk' reduction (or 'risk' increase) compared to the £10 incentive group).